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1780 Research LettersTumor mutational burden and
response to programmed cell death
protein 1 inhibitors in a case series
of patients with metastatic
desmoplastic melanomaTo the Editor: Desmoplastic melanomas (4% of
melanomas) are characterized by spindled melano-
cytes, collagenous or desmoplastic stroma, and an
intense inflammatory response.1 Desmoplastic
melanomas carry a high mutation burden compared
generally with other cancers.2 Programmed cell
death 1 protein (PD-1) inhibitors have been granted
Food and Drug Administration approval for
advanced melanoma as first-line therapy.3 In
addition, a high mutation burden has been
demonstrated as an effective predictor of response
to checkpoint inhibitors, likely due to the increased
neoepitope generation and cytotoxic T-cell
activation. In this study, we examined 12 desmo-
plastic melanomas by using comprehensive genomic
profiling and assessed tumor mutational burden
(TMB) and response to PD-1 inhibitors during
clinical care.
DNA was extracted from 40-methick paraffin-
embedded sections, and comprehensive genomicFig 1. Mutation profile of 12 cases of desmoplasti
ª 2019 by the American Academy of Dermatology, Inc. Published by
Elsevier, Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).profiling was performed on hybridization-captured,
adaptor ligation-based libraries to a mean
coverage depth of[650x for 236 or 315 genes plus
the introns from 19 or 28 genes frequently
involved in cancer. TMB was determined on up to
1.14 Mb of sequenced DNA by using an estimation
algorithm that extrapolates to the genome as a
whole.4
Comprehensive genomic profiling was performed
on 1240 melanoma cases, including 12 desmoplastic
melanomas. A mean of 54 (range 8-128) variants/
sample, which were likely somatic on the basis of
allele frequency, were detected in desmoplastic
samples, and a mean of 22 variants/sample were
predicted to be somatic in nondesmoplastic mela-
nomas (Mann-Whitney-Wilcoxon, P value ¼ .001).
The average TMB in desmoplastic melanomas was
77 mutations/Mb, compared with 35 mutations/Mb
across the remaining 1228melanomas (Fig 1). In 10 of
12 samples, C[T and G[Amutations made up[80%
of the base substitutions, indicating a ultraviolet
lighterelated mutational signature. TP53 was the
most frequently mutated gene (9/12 cases).
Alterations in neurofibromin (NF) genes were
frequent, with NF1 altered in 6 of 12 cases and NF2
altered in 2 of 12 cases, consistent with previous
studies.2 Two cases lackingNF1 orNF2mutations had
NRAS-activating mutations. Other frequently mutated
genes included cyclin-dependent kinase inhibitor 2A
(6/12) and AT-rich interactive domainecontainingc melanoma. TMB, Tumor mutation burden.
Table I. Available demographic information, treatment history, and response to immunotherapy in cases of
desmoplastic melanoma analyzed using CGP
Case no. Age, y Sex Tissue of origin for CGP testing Previous immunotherapy Best response to immunotherapy
1 74 M Skin None Pembrolizumab, PR, 6 mon, ongoing
2 80 M Soft tissue None None
3 51 M Skin 4 doses ipilimumab, PD Pembrolizumab, PR, 11 mon
4 70 M Skin 4 doses ipilimumab, PD Pembrolizumab, SD, 11 mon, ongoing
5 56 M Lung 8 doses of high-dose IL-2, PR Pembrolizumab (no data available)
6 54 M Skin None None
7 81 M Skin 2 doses ipilimumab, PD Pembrolizumab, SD, 2 mon, ongoing
8 29 M Unknown Interferon and ipilimumab, PD Nivolumab, PR, ongoing
9 58 M Skin None None
10 78 M Skin Unknown Unknown
11 67 F Soft tissue Unknown Unknown
12 62 M Skin Unknown Unknown
CGP, Comprehensive genomic profiling; IL, interleukin; PD, progressive disease; PR, partial response; SD, stable disease.
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Of 9 patients with clinical treatment history
available, 6 received a PD-1 inhibitor, and 5 of 5
with available response data had stable disease or
better, including 2 with ongoing partial responses
(Table I). Four of these patients also received prior
treatment with ipilimumab, but none of them
responded.
Our study is limited by our small number of
desmoplastic melanomas and even fewer with
clinical information, but a multi-institutional study in
60 patients with advanced desmoplastic melanoma
treated with varied PD-1 ligand pathway inhibitors
showed a 6-month progression-free survival rate of
77% and 1-year overall survival rate of 80%.5 The
correlation between TMB and response to PD-1
blockade has been reasonably established in the
context of many cancer types, including conventional
melanoma, nonsmall cell lung cancer, and others,
while ultraviolet radiation has been shown to increase
the somatic mutation rate in melanomas. The cases we
have highlighted confirm that desmoplastic mela-
nomas might respond well to PD-1 inhibitors.
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Table I. Baseline demographics and clinical
characteristics for the total population of patients
with psoriasis (N ¼ 37)
Variable Value
Demographics
Median age, y (IQR) 48.0 (39.0-57.5)
Age at diagnosis, y 23.0 (14.0-39.0)
Age at initial treatment, y 48.0 (38.0-45.5)
Women, (%) 17 (46)
Men, (%) 20 (54)
Disease status
Mean duration of disease, y (IQR) 19.0 (11.0-35.5)
Mean baseline PASI (IQR) 13.0 (9.4-16.4)
Medication, n (%)
Ustekinumab-naive group 15 (40.5)
Maintenance group 22 (59.5)
Prior biologic use, n (%) 25 (67.6)
1 biologic 8 (21.6)
2 biologics 10 (27.0)
3 biologics 7 (18.9)
Adalimumab 16 (43.2)
Etanercept 29 (51.3)
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The mean duration of exposure ustekinumab in the maintenance
group before recruitment was 30.6 months.Optimal concentration range of
ustekinumab in patients with
plaque-type psoriasisIQR, Interquartile range; PASI, Psoriasis Area and Severity Index.
To the Editor: Ustekinumab has a better efficacy and
safety profile than earlier antietumor necrosis factor
biologics. Some biologics elicit an unwanted
immune response in the patient by the production
of antidrug antibodies, leading to reduced drug
levels, loss of clinical response, and adverse events.1
Monitoring of ustekinumab levels and antibodies to
ustekinumab (ATUs) may be useful for future clinical
practice to complement clinical assessment and
optimize patient treatment.
The aims of this study were to analyze the
association between serum trough levels of usteki-
numab and treatment response in patients with
psoriasis at 52 weeks and to establish an optimal
concentration range of ustekinumab levels. Patients
were treated with 45 mg of ustekinumab initially and
4 weeks later, followed by 45 mg every 12 weeks.
We recruited 37 patients with moderate-to-severe
psoriasis treated with ustekinumab in an
observational, cross-sectional, prospective, single-
center study (Table I). Blood samples collectedwithin
72 hours before administration of ustekinumab were
analyzed for levels of ustekinumab and ATUs by
enzyme-linked immunosorbent assays with
Promonitor-UTK and Promonitor-ANTI-UTK tests,
respectively (Progenika, Spain).2Disease activity was assessed according to
the Psoriasis Area and Severity Index (PASI) and
clinical improvement (DPASI), as indicated by the
proportion of patients achieving a 75% reduction in
PASI score or the proportion of patients achieving a
90% in PASI score relative to baseline. The Spearman
correlation and Mann-Whitney U test were used to
determine the association between ustekinumab and
PASI score and that between ustekinumab and
clinical response, respectively. Significance was set
at P less than .05.
A significant inverse correlation between
ustekinumab levels and PASI score at week 52
(r ¼ e0.39; P \ .05) was found. The median
concentration of ustekinumab was significantly
higher (P \ .05) in good responders
(DPASI[ 90%) (median concentration 0.47 g/mL
[interquartile range (IQR), 0.31-0.70]) and moderate
responders (75% \ DPASI \ 90%) (median
concentration, 0.32 g/mL [IQR, 55 0.15-0.53]) than
in nonresponders (DPASI\ 75%) (median concen-
tration,\0.131 g/mL [IQR,\0.13 to 0.32]).
Two patients (5.4%) were positive for ATUs,
which is in agreement with other cohort studies
and clinical trials (5.2%-7.0%)3-5 and had no
